Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Smoking Cessation-Pipeline Review, H1 2015

Smoking Cessation-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Smoking Cessation-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Smoking Cessation-Pipeline Review, H1 2015', provides an overview of the Smoking Cessation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Smoking Cessation

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Smoking Cessation

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Smoking Cessation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Smoking Cessation Overview 9

Therapeutics Development 10

Pipeline Products for Smoking Cessation-Overview 10

Pipeline Products for Smoking Cessation-Comparative Analysis 11

Smoking Cessation-Therapeutics under Development by Companies 12

Smoking Cessation-Therapeutics under Investigation by Universities/Institutes 15

Smoking Cessation-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Smoking Cessation-Products under Development by Companies 19

Smoking Cessation-Products under Investigation by Universities/Institutes 20

Smoking Cessation-Companies Involved in Therapeutics Development 21

Aradigm Corporation 21

Arena Pharmaceuticals, Inc. 22

Astraea Therapeutics, LLC 23

Bioprojet SCR 24

Embera NeuroTherapeutics, Inc. 25

FORUM Pharmaceuticals Inc. 26

GlaxoSmithKline plc 27

Invion Limited 28

Johnson & Johnson 29

Marinus Pharmaceuticals, Inc. 30

NAL Pharmaceuticals Ltd. 31

Pfizer Inc. 32

Royalty Pharma 33

Selecta Biosciences, Inc. 34

Targacept, Inc. 35

Zynerba Pharmaceuticals, Inc. 36

Smoking Cessation-Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Combination Products 38

Assessment by Target 39

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

(oxazepam + metyrapone)-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Anatabine-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ARD-1600-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

BP-1.4979-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Drugs to Inhibit FAAH for CNS Disorders-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

encenicline hydrochloride-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

ganaxolone-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

GSK-598809-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

lorcaserin hydrochloride-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

nadolol-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

NIC7-DT-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

nicotine-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

nicotine-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Nicotine Vaccine-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

PF-05402536-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

PF-06413367-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

SEL-068-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Small Molecule for Smoking Cessation-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Small Molecule for Smoking Cessation and Appetite Suppression-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Smoking Cessation-Recent Pipeline Updates 78

Smoking Cessation-Dormant Projects 90

Smoking Cessation-Discontinued Products 91

Smoking Cessation-Product Development Milestones 92

Featured News & Press Releases 92

Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation 92

Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study 93

Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation 94

Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform 95

May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50% 96

Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial 96

Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 97

Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs 98

Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint 99

Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation 99

Appendix 101

Methodology 101

Coverage 101

Secondary Research 101

Primary Research 101

Expert Panel Validation 101

Contact Us 101

Disclaimer 102

List of Tables

Number of Products under Development for Smoking Cessation, H1 2015 10

Number of Products under Development for Smoking Cessation-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Comparative Analysis by Unknown Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Investigation by Universities/Institutes, H1 2015 20

Smoking Cessation-Pipeline by Aradigm Corporation, H1 2015 21

Smoking Cessation-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 22

Smoking Cessation-Pipeline by Astraea Therapeutics, LLC, H1 2015 23

Smoking Cessation-Pipeline by Bioprojet SCR, H1 2015 24

Smoking Cessation-Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 25

Smoking Cessation-Pipeline by FORUM Pharmaceuticals Inc., H1 2015 26

Smoking Cessation-Pipeline by GlaxoSmithKline plc, H1 2015 27

Smoking Cessation-Pipeline by Invion Limited, H1 2015 28

Smoking Cessation-Pipeline by Johnson & Johnson, H1 2015 29

Smoking Cessation-Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 30

Smoking Cessation-Pipeline by NAL Pharmaceuticals Ltd., H1 2015 31

Smoking Cessation-Pipeline by Pfizer Inc., H1 2015 32

Smoking Cessation-Pipeline by Royalty Pharma, H1 2015 33

Smoking Cessation-Pipeline by Selecta Biosciences, Inc., H1 2015 34

Smoking Cessation-Pipeline by Targacept, Inc., H1 2015 35

Smoking Cessation-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 36

Assessment by Monotherapy Products, H1 2015 37

Assessment by Combination Products, H1 2015 38

Number of Products by Stage and Target, H1 2015 40

Number of Products by Stage and Mechanism of Action, H1 2015 42

Number of Products by Stage and Route of Administration, H1 2015 44

Number of Products by Stage and Molecule Type, H1 2015 46

Smoking Cessation Therapeutics-Recent Pipeline Updates, H1 2015 78

Smoking Cessation-Dormant Projects, H1 2015 90

Smoking Cessation-Discontinued Products, H1 2015 91

List of Figures

Number of Products under Development for Smoking Cessation, H1 2015 10

Number of Products under Development for Smoking Cessation-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 37

Number of Products by Top 10 Targets, H1 2015 39

Number of Products by Stage and Top 10 Targets, H1 2015 39

Number of Products by Top 10 Mechanism of Actions, H1 2015 41

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 41

Number of Products by Top 10 Routes of Administration, H1 2015 43

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 43

Number of Products by Top 10 Molecule Types, H1 2015 45

Number of Products by Stage and Top 10 Molecule Types, H1 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aradigm Corporation

Arena Pharmaceuticals, Inc.

Astraea Therapeutics, LLC

Bioprojet SCR

Embera NeuroTherapeutics, Inc.

FORUM Pharmaceuticals Inc.

GlaxoSmithKline plc

Invion Limited

Johnson & Johnson

Marinus Pharmaceuticals, Inc.

NAL Pharmaceuticals Ltd.

Pfizer Inc.

Royalty Pharma

Selecta Biosciences, Inc.

Targacept, Inc.

Zynerba Pharmaceuticals, Inc.

Smoking Cessation Therapeutic Products under Development, Key Players in Smoking Cessation Therapeutics, Smoking Cessation Pipeline Overview, Smoking Cessation Pipeline, Smoking Cessation Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com